Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma

2008 ◽  
Vol 50 (6) ◽  
pp. 1147-1153 ◽  
Author(s):  
Michael J. Absalon ◽  
M. Beth McCarville ◽  
Tiebin Liu ◽  
Victor M. Santana ◽  
Najat C. Daw ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pediatric Patients ◽  
Pulmonary Nodules ◽  
Initial Evaluation

Pulmonary nodules in the initial evaluation of pediatric patients with bone and soft-tissue sarcoma

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 8549-8549
Author(s):  
M. J. Absalon ◽  
M. B. McCarville ◽  
T. Liu ◽  
A. Cain ◽  
F. Navid
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pediatric Patients ◽  
Pulmonary Nodules ◽  
Initial Evaluation

Pulmonary nodules in the initial evaluation of pediatric patients with bone and soft-tissue sarcoma

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 8549-8549
Author(s):  
M. J. Absalon ◽  
M. B. McCarville ◽  
T. Liu ◽  
A. Cain ◽  
F. Navid
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pediatric Patients ◽  
Pulmonary Nodules ◽  
Initial Evaluation

scholarly journals Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group

2019 ◽  
Vol 37 (9) ◽  
pp. 723-730 ◽  
Author(s):  
Bas Vaarwerk ◽  
Gianni Bisogno ◽  
Kieran McHugh ◽  
Hervé J. Brisse ◽  
Carlo Morosi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Overall Survival ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pulmonary Nodules ◽  
Study Group ◽  
Event Free Survival ◽  
Free Survival ◽  
Chest Computed Tomography ◽  
Computed Tomography Scans

Purpose To evaluate the clinical significance of indeterminate pulmonary nodules at diagnosis (defined as ≤ 4 pulmonary nodules < 5 mm or 1 nodule measuring ≥ 5 and < 10 mm) in patients with pediatric rhabdomyosarcoma (RMS). Patients and Methods We selected patients with supposed nonmetastatic RMS treated in large pediatric oncology centers in the United Kingdom, France, Italy, and the Netherlands, who were enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study. Patients included in the current study received a diagnosis between September 2005 and December 2013, and had chest computed tomography scans available for review that were done at time of diagnosis. Local radiologists were asked to review the chest computed tomography scans for the presence of pulmonary nodules and to record their findings on a standardized case report form. In the E pSSG RMS 2005 Study, patients with indeterminate pulmonary nodules were treated identically to patients without pulmonary nodules, enabling us to compare event-free survival and overall survival between groups by log-rank test. Results In total, 316 patients were included; 67 patients (21.2%) had indeterminate pulmonary nodules on imaging and 249 patients (78.8%) had no pulmonary nodules evident at diagnosis. Median follow-up for survivors (n = 258) was 75.1 months; respective 5-year event-free survival and overall survival rates (95% CI) were 77.0% (64.8% to 85.5%) and 82.0% (69.7% to 89.6%) for patients with indeterminate nodules and 73.2% (67.1% to 78.3%) and 80.8% (75.1% to 85.3%) for patients without nodules at diagnosis ( P = .68 and .76, respectively). Conclusion Our study demonstrated that indeterminate pulmonary nodules at diagnosis do not affect outcome in patients with otherwise localized RMS. There is no need to biopsy or upstage patients with RMS who have indeterminate pulmonary nodules at diagnosis.

The diagnosis of pulmonary metastases on chest computed tomography in primary bone sarcoma and musculoskeletal soft tissue sarcoma

2021 ◽  
pp. 20210088
Author(s):  
Asif Saifuddin ◽  
Mirza Shaheer Baig ◽  
Paras Dalal ◽  
Sandra J Strauss
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pulmonary Metastases ◽  
Pulmonary Nodules ◽  
Bone Sarcoma ◽  
Musculoskeletal Sarcoma ◽  
Extremity Soft Tissue Sarcoma ◽  
Primary Bone Sarcoma ◽  
Primary Bone ◽  
Current Article

The lungs are the commonest site of metastasis for primary high-grade bone and soft tissue sarcoma, but current guidelines on the management of pulmonary nodules do not specifically cater for this group of patients. The current article reviews the literature from the past 20 years that has reported the CT features of pulmonary metastases in the setting of known primary bone and soft tissue sarcoma, with emphasis on osteosarcoma, chondrosarcoma, and trunk and extremity soft tissue sarcoma, the aim being to aid radiologists who report chest CT of musculoskeletal sarcoma patients in deciding which lesions should be considered metastatic, which lesions are indeterminate and require follow-up, and which lesions are of no concern.

Clinical Features and Outcome of Initially Unresected Nonmetastatic Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma

2002 ◽  
Vol 20 (15) ◽  
pp. 3225-3235 ◽  
Author(s):  
Sheri L. Spunt ◽  
D. Ashley Hill ◽  
Alison M. Motosue ◽  
Catherine A. Billups ◽  
Alvida M. Cain ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Neoadjuvant Therapy ◽  
Clinical Features ◽  
Pediatric Patients ◽  
Residual Tumor ◽  
Response To Therapy ◽  
Outcome Analysis ◽  
Limiting Factor

PURPOSE: To describe the clinical features, response to therapy, and outcome of pediatric patients with initially unresected nonmetastatic nonrhabdomyosarcoma soft tissue sarcoma (NRSTS). PATIENTS AND METHODS: We retrospectively reviewed the presenting clinical features and tumor characteristics of all 40 pediatric patients with initially unresected nonmetastatic NRSTS who were seen at our institution between March 1962 and December 1996. A subset of 27 patients for whom complete treatment information was available was analyzed to determine whether response to therapy was associated with local disease control and event-free and overall survival. RESULTS: More than 70% of the 40 patients had tumors with high-risk features (tumor size > 5 cm, high grade, invasiveness). For the 27 patients included in the outcome analysis, 5-year event-free survival and survival estimates were 33% ± 9% and 56% ± 10%, respectively. Ten (37%) of these patients had a complete or partial response to neoadjuvant chemotherapy and/or radiotherapy, and only two of the 10 had residual tumor after surgery. Combined chemotherapy and radiotherapy seemed more effective than either modality alone in inducing a response, but the response to neoadjuvant therapy did not predict outcome. Most treatment failures were local, and postrelapse survival was poor (19% ± 10%). CONCLUSION: Initially unresected NRSTS constitutes a unique subgroup of pediatric sarcomas that commonly present with high-risk features and respond poorly to neoadjuvant therapy. Only about one third of patients treated with multimodal therapy remain disease-free, and local control is the major limiting factor in achieving cure. More effective risk-directed treatments are needed for this unique subgroup of patients.

scholarly journals FDG PET/CT for Evaluating Early Response to Neoadjuvant Chemotherapy in Pediatric Patients with Sarcoma: A Prospective Single-Center Trial

2020 ◽  
Author(s):  
Giulia Polverari ◽  
Francesco Ceci ◽  
Roberto Passera ◽  
Jacquelyn Crane ◽  
Lin Du ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Pediatric Patients ◽  
Early Response ◽  
Secondary Outcome ◽  
Single Center ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Introduction: This is a prospective, single-center trial (UCLA-IRB#10-000246) in pediatric patients with high-grade bone or soft tissue sarcoma. The aim was to evaluate FDG-PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX).Methods: Bone or soft tissue sarcoma patients with i) baseline FDG PET/CT within four weeks prior to the start of neo-CTX (PET1), ii) early interim FDG PET/CT (six weeks after the start of neo-CTX (PET2), iii) evaluation of neo-CTX response by histology or MRI, and iv) definitive therapy after neo-CTX (surgery or radiation) were included. Semi-quantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were calculated. Patients with necrosis ≥90% in the excised tumor tissue after surgery or with complete disappearance of the soft tissue component on MRI after neo-CTX were considered responders. The primary endpoint was to evaluate the predictive value of FDG PET/CT parameters at baseline and early during neo-CTX for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if FDG PET/CT can predict the response to neo-CTX assessed by percentage of necrosis in the resected tumor or post-treatment MRI. Primary and secondary outcomes were also evaluated in a sub-population of patients with bone involvement only.Results: Thirty-four consecutive patients were enrolled (10 females; 24 males; median age=15.1 years). 17/34 patients (50%) had Osteosarcoma, 13/34 (38%) Ewing Sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44.1%) and 19/34 (55.9%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p <0.02). ΔMTV was associated with tissue response to neo-CTX (p=0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS. Conclusion: FDG PET/CT performed six weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric bone and soft tissue sarcoma patients.

scholarly journals Aural polyp with facial asymmetry in an unfortunate infant

2021 ◽  
Vol 16 (1) ◽  
pp. 133-135
Author(s):  
Farah Syahida Zubir ◽  
Jeyasakthy Saniasiaya ◽  
Haslinda Abdul Gani
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Temporal Bone ◽  
Early Treatment ◽  
Pediatric Patients ◽  
Facial Asymmetry ◽  
Ear Infection ◽  
Aural Polyp ◽  
History Of

Temporal bone rhabdomyosarcoma is an aggressive entity that simulates chronic otitis ear infection. It is the most common soft tissue sarcoma amongst pediatric patients. Herein, we would like to report a case of temporal bone rhabdomyosarcoma involving a 2-year-old boy who presented with a one-month history of otorrhea with facial asymmetry. Early treatment led to remission of this severe neoplasm.

Response to Pazopanib in Two Pediatric Patients with Pretreated Relapsing Synovial Sarcoma

2017 ◽  
Vol 103 (1) ◽  
pp. e1-e3 ◽  
Author(s):  
Michela Casanova ◽  
Eleonora Basso ◽  
Chiara Magni ◽  
Luca Bergamaschi ◽  
Stefano Chiaravalli ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Children And Adolescents ◽  
Synovial Sarcoma ◽  
Pediatric Patients ◽  
Adult Patients ◽  
New Drugs ◽  
Multikinase Inhibitor ◽  
New Agents ◽  
Prolonged Response

Pazopanib is an oral multikinase inhibitor that has proved effective in adults treated for relapsing soft tissue sarcoma and synovial sarcoma in particular. Two cases are reported here of pediatric patients with pretreated relapsing synovial sarcoma whose tumors showed a prolonged response to pazopanib given on compassionate grounds. These results suggest that new agents found effective in adult patients might achieve similar results in adolescents with the same disease. Facilitating the availability of new drugs for children and adolescents is a major challenge for pediatric oncologists.

scholarly journals Clinical and Radiologic Features Together Better Predict Lung Nodule Malignancy in Patients with Soft-Tissue Sarcoma

2020 ◽  
Vol 9 (4) ◽  
pp. 1209
Author(s):  
Cecilia Tetta ◽  
Antonio Giugliano ◽  
Laura Tonetti ◽  
Michele Rocca ◽  
Alessandra Longhi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Primary Tumor ◽  
Treatment Options ◽  
Lung Nodule ◽  
Pulmonary Nodules ◽  
Logistic Regression Models ◽  
Preoperative Ct ◽  
Ct Features ◽  
New Onset

We test the hypothesis that a model including clinical and computed tomography (CT) features may allow discrimination between benign and malignant lung nodules in patients with soft-tissue sarcoma (STS). Seventy-one patients with STS undergoing their first lung metastasectomy were examined. The performance of multiple logistic regression models including CT features alone, clinical features alone, and combined features, was tested to evaluate the best model in discriminating malignant from benign nodules. The likelihood of malignancy increased by more than 11, 2, 6 and 7 fold, respectively, when histological synovial sarcoma sub-type was associated with the following CT nodule features: size ≥ 5.6 mm, well defined margins, increased size from baseline CT, and new onset at preoperative CT. Likewise, in the case of grade III primary tumor, the odds ratio (OR) increased by more than 17 times when the diameter of pulmonary nodules (PNs) was >5.6 mm, more than 13 times with well-defined margins, more than 7 times with PNs increased from baseline CT, and more than 20 times when there were new-onset nodules. Finally, when CT nodule was ≥5.6 in size, it had well-defined margins, it increased in size from baseline CT, and when new onset nodules at preoperative CT were concomitant to residual primary tumor R2, the risk of malignancy increased by more than 10, 6, 25 and 28 times, respectively. The combination of clinical and CT features has the highest predictive value for detecting the malignancy of pulmonary nodules in patients with soft tissue sarcoma, allowing early detection of nodule malignancy and treatment options.

Sign in / Sign up

Export Citation Format

Share Document